Shaping the future of animal health
Virbac group
Responsibility contact
For more information about our actions in this field, please e-mail us: developpement.

Economic performance

Dedicated exclusively to animal health for nearly fifty years, Virbac aims to continue its development in harmony with its environment and with the people who work for it. It also wants to ensure the continuity of the Group through sustainable and profitable growth. In 2015, Virbac experienced growth led by the acquisition of the Sentinel range in the United States and favourable exchange rates. Virbac’s organic growth reduced by -5.4% over the year. Outside of the United States, which experienced an exceptional situation in 2015 linked to the temporary suspension of manufacture and deliveries from the St. Louis site, organic growth rose by +3.0%.

As part of its strategy, Virbac supports its development through regular new product launches, the strength of its large portfolio and global presence reaching into all the major markets in both developed and emerging countries. This controlled-growth strategy is reflected by a steady growth in revenues and the workforce. Virbac also benefits from a stable shareholder family which favours constant and long-term progress over short-term goals. In terms of sub-contracted production activities (licensing products or production sub-contracted to a third party), they represent over 30% of the Group’s sales in 2015, due to the acquisition of the Sentinel products currently manufactured externally. The suppliers in charge of manufacturing these products are managed according to the evaluation procedures described in the G4-HR5 and G4-HR10 indicators.

Change in revenue (€ million) and Group staff numbers
Change in net income and market capitalisation (€ million)

Virbac sustains a policy of investment and innovation, which ensures the continuity and independence of the company. Also, thanks to controlled debt, Virbac is able to pursue internal and external growth with full independence. The resources thus deployed favour financing innovation that is oriented towards satisfying customer needs.

In 2015, the resources devoted to innovation (research, development, licensing) strongly improved (+12.5%) compared with the previous year and represent 7.9% of the revenues. In parallel, the Group continues to use its investing capacity to accompany its development through targeted external growth (acquisition of companies, of products, of active ingredients etc.) and to finance an investment programme particularly in industrial projects. 

R&D and Licensing costs 
(€ million)
Net debt / equity - 
Group share (%)


Figures for 2015 include the financing of the purchase of the Sentinel brands in the United States.


Share on Google Share on Facebook Print current page